SABCS Highlights
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read More ›
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read More ›
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer. Read More ›
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more.
Read More ›
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
Read More ›
Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. Read More ›
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Read More ›